Plain-English translation of NCT05080946 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ovarian Cancer research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing whether aspirin—a common, affordable pain reliever—can help your body's immune system fight ovarian cancer better when taken alongside chemotherapy. Researchers want to see if this medication can reduce the immune-suppressing signals that tumors use to hide from the body's natural defenses. About 100 women will participate, and half will receive aspirin while the other half receive a placebo (a pill with no active ingredient).
Ovarian cancer tumors are often very good at turning off the immune system so it cannot fight back. Researchers think this medication might help reverse that process and give patients' immune systems a better chance of working alongside chemotherapy to destroy cancer cells.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be randomly assigned to take either aspirin (325 mg daily) or a placebo pill while receiving your planned chemotherapy. You will keep a pill diary to track whether you took your daily pill, attend regular clinic visits for blood tests and check-ins, and provide a small tissue sample from your cancer (or use an existing sample if available). At the time of your interval debulking surgery—the operation planned after your chemotherapy—researchers will collect additional tissue to measure changes in immune markers, and you'll complete a final questionnaire.
AI-generated summary from trial data · Jul 16, 2026 · Not medical advice
United States